On this episode of Molecular Moments, Lynn Kamen, Ph.D., and Michelle Miller, Ph.D. DABT discuss their very different journeys to
In our latest Team Q&A blog, we talk to Charlie Walker, Associate Director of Finance at BioAgilytix, to learn more about his role, why he felt drawn to the bioanalytical industry, and how he gets to see the team’s work play out in exciting ways, and for the benefit of patients in need.
Today we’re featuring a case study on how BioAgilytix developed a cell-based assay to determine the prevalence of pre-existing antibodies against the AAV9 serotype in patients for a gene therapy clinical trial.
In this Q&A session we talk to David Rusnak, one of the first 3 employees to join BioAgilytix when it was founded 10 years ago and currently our Director of Laboratory Systems and Automation, to learn more about his experience growing with the organization from its very start – and what still keeps him excited to come to work each day.
In this Q&A session, we speak to longtime BioAgilytix Europe team member Gabi Schewe – who has been with the company since its founding as IPM Biotech in 1996 – to hear about the exciting and historic scientific advancements she has been part of with the company and what she believes has made its long-term success possible.
A knowledgeable and committed CRO partner can make all the difference in a stalled out study, which in the right hands could go on to create a life-changing therapeutic innovation. We discuss what to look for in a “rescue project” partner.
We’ve compiled some key questions to consider when selecting an outsourced partner for bioanalysis, so that you can set your large molecule study up for success from the very start.
With headquarters in the USA and Europe, effective team-wide communication is critical to our success. William Hunter, Director of BD & Global Key Accounts at BioAgilytix Europe, and Todd Lester, BPM at our USA HQ, discuss how they collaborate.
In this Team Q&A session, Dave Williams, Director, Bioanalytical Operations at BioAgilytix, talks with us about why he made the move from Kansas City to join the BioAgilytix team in 2017, and the ways in which his role has evolved in just one year.
The rapidly changing bioanalytical industry can make it challenging for CROs to keep up with technology demands. However, organizations that establish strong and responsive partnerships with sponsor companies will be in the best position to deliver new value through new technology.